Drug intelligence / Profile preview

sevoflurane + isoflurane + desflurane + remifentanil

Development stage: Unknown
Lead developer: Ohio Medical Products
Modality: Small Molecules
Administration: Inhalation, Intravenous

Overview

This is a combination of three volatile inhalational anesthetics (sevoflurane, isoflurane, and desflurane) and one intravenous opioid analgesic (remifentanil). These agents are used individually or in various combinations during general anesthesia procedures. The volatile anesthetics provide unconsciousness and amnesia, while remifentanil provides potent analgesia with an ultra-short duration of action. This specific combination of all four agents would not typically be administered simultaneously but represents options available to anesthesiologists for different phases or types of anesthesia.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on sevoflurane + isoflurane + desflurane + remifentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sevoflurane + isoflurane + desflurane + remifentanil.

Explore the full profile